贝前列素钠联合利拉鲁肽对老年糖尿病肾病患者肾功能及血清学指标的影响  

Effects of beraprost sodium combined with liraglutide on renal function and serological indexes in elderly patients with diabetes nephropathy

作　　者：方泽源 张义鹏 朱晓燕 Fang Ze-yuan;Zhang Yi-peng;Zhu Xiao-yan(Department of Geriatrics and Endocrinology,Xuchang Hospital of Traditional Chinese Medicine,Xuchang 461000,Henan,China)

机构地区：[1]许昌中医院老年病、内分泌科,河南许昌461000

出　　处：《四川生理科学杂志》2025年第4期826-829,共4页

摘　　要：目的:探讨贝前列素钠联合利拉鲁肽对老年糖尿病肾病(Diabetic kidney disease,DKD)患者肾功能及血清学指标的影响。方法:回顾性分析2022年9月至2024年2月于我院采用利拉鲁肽0.6 mg·d-1治疗的99例老年DKD患者临床资料为对照组,以及同期采用贝前列素钠(40μg,3次·d-1)联合利拉鲁肽治疗的101例老年DKD患者资料为联合组。持续治疗3 m后,观察临床疗效、不良反应总发生率,于治疗前、治疗3 m后采用糖化血红蛋白仪检测糖化血红蛋白(Glycated hemoglobin,HbA1c),采用全自动生化分析仪检测空腹血糖(Fasting plasma glucose,FPG)、餐后2 h血糖(2-Hour postprandial plasma glucose,2hPG)、血肌酐(Serum creatinine,Scr)、尿素氮(Blood urea nitrogen,BUN)水平,采用免疫比浊法检测24 h尿蛋白定量(24-Hour urinary protein quantity,24h-UTP)水平,采用免疫散射比浊法测定半胱氨酸蛋白酶抑制剂C(Cystatin C,Cys-C)、尿β_(2)微球蛋白(Urineβ_(2)-microglobulin,β_(2)-MG)水平并计算尿白蛋白排泄率(Urine albumin excretion rate,UAER),同时采用酶联免疫吸附法测定白细胞介素-1β(Interleukin-1β,IL-1β)、转化生长因子-β1(Transforming growth factor-β1,TGF-β1)、内皮素-1(Endothelin-1,ET-1)水平。结果:联合组总有效率94.06%高于对照组84.85%(P<0.05);治疗3 m后,联合组24 h-UTP、FPG、2 h-PG、HbA1c均低于对照组(P<0.05);治疗3m后,两组Scr、BUN、β_(2)-MG、UAER、IL-1β、TGF-β1、Cys-C、ET-1均下降,其中联合组下降幅度更大(P<0.05);两组不良反应总发生率无明显差异(P>0.05)。结论:贝前列素钠联合利拉鲁肽治疗老年DKD患者效果显著,可降低患者血糖及24 h-UTP水平,改善肾功能,减轻炎症反应。Objective:To explore the effect of beraprost sodium combined with liraglutide on renal function and serological indicators in elderly patients with diabetic kidney disease(DKD).Method:Retrospective analysis of clinical data of 99 elderly patients with DKD treated with liraglutide 0.6 mg•day-1 in our hospital from September 2022 to February 2024 as the control group,and 101 elderly patients with DKD treated with bepridil sodium(40μg,3 times•day-1)combined with liraglutide as the combined group.After 3 months of continuous treatment,the clinical efficacy and total incidence of adverse reactions were observed.Glycated hemoglobin(HbA1c)was measured using a glycated hemoglobin analyzer before and after treatment.Fasting plasma glucose(FPG),2-hour postprandial plasma glucose(2hPG),serum creatinine(Scr),and blood urea nitrogen(BUN)levels were measured using a fully automated biochemical analyzer.The 24-hour urinary protein quantity(24h-UTP)level was detected using immunoturbidimetry.The levels of cystatin C(Cys-C)and urineβ_(2)-microglobulin(β_(2)-MG)were determined using immune scattering turbidimetry,and the urinary albumin excretion rate(UAER)was calculated.At the same time,the levels of interleukin-1β(IL-1β),transforming growth factor-β1(TGF-β1),and endothelin-1(ET-1)were measured using enzyme-linked immunosorbent assay.Results:The total effective rate of the combined group was 94.06%,which was higher than that of the control group(84.85%)(P<0.05).After 3 months of treatment,the combined group had lower levels of 24h-UTP,FPG,2h-PG,and HbA1c than the control group(P<0.05).After 3 months of treatment,Scr,BUN,β_(2)-MG,UAER,IL-1β,TGF-β1,Cys-C,and ET-1 in both groups decreased,with a greater decrease in the combined group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combination of beraprost sodium and liraglutide has significant therapeutic effects in treating elderly patients with DKD,reducing blood glucose and 24-hour

关 键 词：贝前列素钠 利拉鲁肽 糖尿病肾病 肾功能 血清学指标 

分 类 号：R587.2[医药卫生—内分泌]